SimianX AI LogoSimianX AI

Asset profile

VAX-31 · Vaxcyte (PCVX)

Indication
prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia
Also known as
VAX-31, 31-valent PCV, 31-valent pneumococcal conjugate vaccine, VAX-31 High Dose
CompanyPCVXVaxcyte

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate a…

Start live analysis of PCVXRun 8-agent AI analysis

On the calendar

Timeline

Newest first.

Registered trials

Registry IDPhaseStatusPrimary completionEnrollmentSites
NCT06151288Phase 1/2CompletedJul 17, 2024101525 of 25 sites in the United States
NCT07425392Phase 3Active, not recruitingMar 1, 202775230 of 30 sites in the United States
NCT06720038Phase 2Active, not recruitingDec 1, 202790045 of 48 sites in the United States
NCT07365826Phase 3Active, not recruitingMar 1, 2027139025 of 25 sites in the United States
NCT07284654Phase 3CompletedSep 17, 2026404930 of 30 sites in the United States
VAX-31 · Vaxcyte (PCVX) — FDA Timeline & Readiness Checklist | SimianX AI